TR200101261T2 - Uzun süreli salınımlı ranolazin formülasyonları. - Google Patents

Uzun süreli salınımlı ranolazin formülasyonları.

Info

Publication number
TR200101261T2
TR200101261T2 TR2001/01261T TR200101261T TR200101261T2 TR 200101261 T2 TR200101261 T2 TR 200101261T2 TR 2001/01261 T TR2001/01261 T TR 2001/01261T TR 200101261 T TR200101261 T TR 200101261T TR 200101261 T2 TR200101261 T2 TR 200101261T2
Authority
TR
Turkey
Prior art keywords
ranolazine
prolonged
inhibitor
release ranolazine
ranolazine formulations
Prior art date
Application number
TR2001/01261T
Other languages
English (en)
Turkish (tr)
Inventor
A. Wolff Andrew
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200101261(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Publication of TR200101261T2 publication Critical patent/TR200101261T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
TR2001/01261T 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları. TR200101261T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (1)

Publication Number Publication Date
TR200101261T2 true TR200101261T2 (tr) 2002-05-21

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/01261T TR200101261T2 (tr) 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları.
TR2001/01262T TR200101262T2 (tr) 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/01262T TR200101262T2 (tr) 1998-09-10 1999-09-09 Uzun süreli salınımlı ranolazin formülasyonları

Country Status (33)

Country Link
US (14) US6303607B1 (e)
EP (3) EP1096937B9 (e)
JP (2) JP3745621B2 (e)
KR (1) KR100475759B1 (e)
CN (2) CN1211086C (e)
AR (3) AR022085A1 (e)
AT (2) ATE217794T1 (e)
AU (4) AU760435B2 (e)
BR (2) BR9913626A (e)
CA (2) CA2342390C (e)
CY (1) CY2008020I1 (e)
CZ (2) CZ301375B6 (e)
DE (3) DE122008000065I1 (e)
DK (2) DK1096937T3 (e)
ES (2) ES2177346T3 (e)
FR (1) FR09C0001I2 (e)
GE (1) GEP20053420B (e)
HK (1) HK1044284B (e)
HU (2) HU224215B1 (e)
IL (6) IL141893A0 (e)
LU (1) LU91504I2 (e)
MX (2) MXPA01002598A (e)
NL (1) NL300371I2 (e)
NO (4) NO319434B1 (e)
NZ (2) NZ510386A (e)
PL (3) PL196263B1 (e)
PT (2) PT1109558E (e)
RU (2) RU2214233C2 (e)
SI (2) SI1096937T1 (e)
TR (2) TR200101261T2 (e)
TW (1) TWI241911B (e)
UA (2) UA75027C2 (e)
WO (2) WO2000013686A2 (e)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
CA2398691A1 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
ES2523873T3 (es) 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
JP2008526879A (ja) * 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
EP1909767A2 (en) * 2005-07-28 2008-04-16 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
JP5672648B2 (ja) * 2006-03-17 2015-02-18 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置および照明装置
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
WO2008150565A2 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) * 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
NO3175985T3 (e) 2011-07-01 2018-04-28
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
DE69034000T2 (de) * 1989-06-23 2003-06-05 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zum Schutz der Skelettmuskulatur
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
EP1096937B9 (en) 2007-02-28
US20030166659A1 (en) 2003-09-04
US20020090396A1 (en) 2002-07-11
IL141893A (en) 2008-08-07
AR022085A1 (es) 2002-09-04
EP1527779A1 (en) 2005-05-04
DK1096937T3 (da) 2005-05-09
CN1193757C (zh) 2005-03-23
BR9913553A (pt) 2001-10-23
IL141893A0 (en) 2002-03-10
NO2009005I1 (no) 2009-03-16
NO20054324L (no) 2001-04-30
CA2342390C (en) 2006-08-29
IL180864A0 (en) 2007-07-04
US20040029890A1 (en) 2004-02-12
WO2000013687A3 (en) 2000-06-29
LU91504I9 (e) 2019-01-02
JP3745621B2 (ja) 2006-02-15
PT1096937E (pt) 2005-04-29
ES2234302T3 (es) 2005-06-16
DE69901570D1 (de) 2002-06-27
AU760435B2 (en) 2003-05-15
AU6142599A (en) 2000-03-27
CY2008020I2 (el) 2010-07-28
EP1109558B1 (en) 2002-05-22
CN1211086C (zh) 2005-07-20
US20060217397A1 (en) 2006-09-28
US20060147521A1 (en) 2006-07-06
AU744071B2 (en) 2002-02-14
NZ510386A (en) 2003-08-29
AU2008207707A1 (en) 2008-09-25
CY2008020I1 (el) 2010-07-28
US6620814B2 (en) 2003-09-16
US20040097514A1 (en) 2004-05-20
TR200101262T2 (tr) 2001-12-21
JP2006096757A (ja) 2006-04-13
CA2343376C (en) 2007-01-09
CA2343376A1 (en) 2000-03-16
KR20010089874A (ko) 2001-10-12
ATE285774T1 (de) 2005-01-15
EP1096937B1 (en) 2004-12-29
US6617328B2 (en) 2003-09-09
UA67793C2 (uk) 2004-07-15
PL348249A1 (en) 2002-05-20
US6303607B1 (en) 2001-10-16
TWI241911B (en) 2005-10-21
PL202207B1 (pl) 2009-06-30
US20050059667A1 (en) 2005-03-17
SI1109558T1 (en) 2002-10-31
AU2008207703A1 (en) 2008-09-25
KR100475759B1 (ko) 2005-03-10
PL196263B1 (pl) 2007-12-31
US20020004506A1 (en) 2002-01-10
NL300371I2 (nl) 2009-10-01
LU91504I2 (fr) 2009-02-03
US6562826B1 (en) 2003-05-13
US6864258B2 (en) 2005-03-08
CN1321088A (zh) 2001-11-07
AR053440A2 (es) 2007-05-09
DK1109558T3 (da) 2002-08-26
HUP0103844A2 (hu) 2002-04-29
ATE217794T1 (de) 2002-06-15
WO2000013687A2 (en) 2000-03-16
US6852724B2 (en) 2005-02-08
AU6036499A (en) 2000-03-27
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
CZ2001879A3 (cs) 2001-08-15
NO20011192L (no) 2001-04-30
US20050153982A1 (en) 2005-07-14
UA75027C2 (uk) 2006-03-15
GEP20053420B (en) 2005-01-25
US6369062B1 (en) 2002-04-09
NO2009005I2 (e) 2010-06-28
HUP0103844A3 (en) 2002-11-28
NZ510384A (en) 2002-10-25
HUP0104088A2 (hu) 2002-05-29
WO2000013686A3 (en) 2000-07-06
DE122008000065I1 (de) 2009-04-09
DE69901570T2 (de) 2003-01-09
CZ2001880A3 (cs) 2001-08-15
SI1096937T1 (en) 2005-04-30
IL141892A0 (en) 2002-03-10
DE69922964D1 (de) 2005-02-03
US20030100566A1 (en) 2003-05-29
AR052921A1 (es) 2007-04-11
HK1044284B (zh) 2005-07-15
MXPA01002598A (es) 2002-04-08
HK1040060A1 (en) 2002-05-24
RU2214233C2 (ru) 2003-10-20
RU2207856C2 (ru) 2003-07-10
HUP0104088A3 (en) 2002-12-28
PT1109558E (pt) 2002-10-31
US6525057B2 (en) 2003-02-25
NO20011192D0 (no) 2001-03-08
EP1109558A2 (en) 2001-06-27
HU224215B1 (hu) 2005-06-28
DE69922964T2 (de) 2005-12-08
FR09C0001I2 (e) 2009-12-18
NO20011191D0 (no) 2001-03-08
CA2342390A1 (en) 2000-03-16
ES2177346T3 (es) 2002-12-01
MXPA01002599A (es) 2005-02-17
HK1044284A1 (en) 2002-10-18
CN1354665A (zh) 2002-06-19
US20030099705A1 (en) 2003-05-29
PL196668B1 (pl) 2008-01-31
IL141892A (en) 2006-08-20
NO320986B1 (no) 2006-02-20
JP2002524416A (ja) 2002-08-06
NL300371I1 (nl) 2009-02-02
US6503911B2 (en) 2003-01-07
IL175371A0 (en) 2006-09-05
CZ301375B6 (cs) 2010-02-03
CZ301341B6 (cs) 2010-01-20
EP1096937A2 (en) 2001-05-09
NO319434B1 (no) 2005-08-15
NO20011191L (no) 2001-04-30
BR9913626A (pt) 2001-12-04
FR09C0001I1 (e) 2009-02-27

Similar Documents

Publication Publication Date Title
TR200101261T2 (tr) Uzun süreli salınımlı ranolazin formülasyonları.
WO2001066093A3 (en) Sustained release ranolazine formulations
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
NO20083842L (no) Anvendelse av opploselig lymfotoksin-beta-reseptor for fremstilling av medikamenter
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
WO1997045091A3 (en) Sustained release oxycodone formulations with no fed/fast effect
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
IS5283A (is) Lyfjasamsetningar sem innihalda eletriptan hemisúlfat og koffín
DE3876773D1 (de) Pharmazeutische zusammensetzungen.
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
PL346764A1 (en) New oral formulation for 5-ht4
DE69906963D1 (de) Efavirenz enthaltende gepresste tablettenformulierug
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
YU28002A (sh) Farmaceutska kompozicija koja sadrži ciklesonid za primenu na sluzokoži
TR200100896T2 (tr) İkameli propanol türevleri, imalat yöntemleri, bileşimleri içeren ilaçlar, kullanımları
SE0001916D0 (sv) Novel formulation
DE69408579D1 (de) Asserlösliche pharmazeutische zusammensetzungen, die östronderivate und kalziumsalze enthalten
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
MXPA01011842A (es) Composiciones farmaceuticas para la administracion oral de floroglucinol y preparacion de las mismas.
DE3776111D1 (de) Pharmazeutische zubereitungen.
SE9604752D0 (sv) Formulation and use